Phosphate control in end-stage renal disease: Barriers and opportunities

Ahmed A. Waheed, Fernando Pedraza, Oliver Lenz, Tamara Isakova

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Hyperphosphatemia is a nearly universal complication of endstage renal disease that is widely recognized as one of the most important and most challenging clinical targets to meet in the care of dialysis patients. Left untreated, it can lead to bone pain, pruritus and worsening secondary hyperparathyroidism. Data from observational studies demonstrate that an elevated serum phosphorus level is an independent risk factor for mortality, and that treatment with phosphate binders is independently associated with improved survival. Experimental studies provide support for the epidemiologic findings: phosphate excess promotes vascular calcification, induces endothelial dysfunction and may contribute to other emerging chronic kidney disease-specific mechanisms of cardiovascular toxicity. On the basis of this evidence, clinical practice guidelines recommend specific targets for serum phosphorus levels in the dialysis population. The purpose of this review is to summarize common challenges in meeting these targets and to identify potential opportunities for improvement.

Original languageEnglish
Pages (from-to)2961-2968
Number of pages8
JournalNephrology Dialysis Transplantation
Volume28
Issue number12
DOIs
StatePublished - Dec 1 2013

Fingerprint

Phosphorus
Chronic Kidney Failure
Dialysis
Phosphates
Hyperphosphatemia
Vascular Calcification
Secondary Hyperparathyroidism
Pruritus
Serum
Chronic Renal Insufficiency
Practice Guidelines
Observational Studies
Patient Care
Kidney
Bone and Bones
Pain
Mortality
Population
Therapeutics

Keywords

  • Dialysis
  • Phosphate binders
  • Phosphorus

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

Phosphate control in end-stage renal disease : Barriers and opportunities. / Waheed, Ahmed A.; Pedraza, Fernando; Lenz, Oliver; Isakova, Tamara.

In: Nephrology Dialysis Transplantation, Vol. 28, No. 12, 01.12.2013, p. 2961-2968.

Research output: Contribution to journalArticle

Waheed, Ahmed A. ; Pedraza, Fernando ; Lenz, Oliver ; Isakova, Tamara. / Phosphate control in end-stage renal disease : Barriers and opportunities. In: Nephrology Dialysis Transplantation. 2013 ; Vol. 28, No. 12. pp. 2961-2968.
@article{a12df7b37dc7412aa8b71049eec6d99e,
title = "Phosphate control in end-stage renal disease: Barriers and opportunities",
abstract = "Hyperphosphatemia is a nearly universal complication of endstage renal disease that is widely recognized as one of the most important and most challenging clinical targets to meet in the care of dialysis patients. Left untreated, it can lead to bone pain, pruritus and worsening secondary hyperparathyroidism. Data from observational studies demonstrate that an elevated serum phosphorus level is an independent risk factor for mortality, and that treatment with phosphate binders is independently associated with improved survival. Experimental studies provide support for the epidemiologic findings: phosphate excess promotes vascular calcification, induces endothelial dysfunction and may contribute to other emerging chronic kidney disease-specific mechanisms of cardiovascular toxicity. On the basis of this evidence, clinical practice guidelines recommend specific targets for serum phosphorus levels in the dialysis population. The purpose of this review is to summarize common challenges in meeting these targets and to identify potential opportunities for improvement.",
keywords = "Dialysis, Phosphate binders, Phosphorus",
author = "Waheed, {Ahmed A.} and Fernando Pedraza and Oliver Lenz and Tamara Isakova",
year = "2013",
month = "12",
day = "1",
doi = "10.1093/ndt/gft244",
language = "English",
volume = "28",
pages = "2961--2968",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Phosphate control in end-stage renal disease

T2 - Barriers and opportunities

AU - Waheed, Ahmed A.

AU - Pedraza, Fernando

AU - Lenz, Oliver

AU - Isakova, Tamara

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Hyperphosphatemia is a nearly universal complication of endstage renal disease that is widely recognized as one of the most important and most challenging clinical targets to meet in the care of dialysis patients. Left untreated, it can lead to bone pain, pruritus and worsening secondary hyperparathyroidism. Data from observational studies demonstrate that an elevated serum phosphorus level is an independent risk factor for mortality, and that treatment with phosphate binders is independently associated with improved survival. Experimental studies provide support for the epidemiologic findings: phosphate excess promotes vascular calcification, induces endothelial dysfunction and may contribute to other emerging chronic kidney disease-specific mechanisms of cardiovascular toxicity. On the basis of this evidence, clinical practice guidelines recommend specific targets for serum phosphorus levels in the dialysis population. The purpose of this review is to summarize common challenges in meeting these targets and to identify potential opportunities for improvement.

AB - Hyperphosphatemia is a nearly universal complication of endstage renal disease that is widely recognized as one of the most important and most challenging clinical targets to meet in the care of dialysis patients. Left untreated, it can lead to bone pain, pruritus and worsening secondary hyperparathyroidism. Data from observational studies demonstrate that an elevated serum phosphorus level is an independent risk factor for mortality, and that treatment with phosphate binders is independently associated with improved survival. Experimental studies provide support for the epidemiologic findings: phosphate excess promotes vascular calcification, induces endothelial dysfunction and may contribute to other emerging chronic kidney disease-specific mechanisms of cardiovascular toxicity. On the basis of this evidence, clinical practice guidelines recommend specific targets for serum phosphorus levels in the dialysis population. The purpose of this review is to summarize common challenges in meeting these targets and to identify potential opportunities for improvement.

KW - Dialysis

KW - Phosphate binders

KW - Phosphorus

UR - http://www.scopus.com/inward/record.url?scp=84890016275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890016275&partnerID=8YFLogxK

U2 - 10.1093/ndt/gft244

DO - 10.1093/ndt/gft244

M3 - Article

C2 - 23901051

AN - SCOPUS:84890016275

VL - 28

SP - 2961

EP - 2968

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 12

ER -